Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $18,474 | $22,405 |
| General and administrative | 8,791 | 4,124 |
| Total operating expenses | 27,265 | 26,529 |
| Loss from operations | (27,265) | (26,529) |
| Interest and other income, net | 3,748 | 2,649 |
| Net loss | $(23,517) | $(23,880) |
| Unrealized loss on marketable securities | (892) | (2) |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s R&D?
- MBX Biosciences, Inc. (MBX) reported R&D of $18.47M in Q1 2026.
- How has MBX Biosciences, Inc.'s R&D changed year-over-year?
- MBX Biosciences, Inc.'s R&D decreased by 17.5% year-over-year, from $22.41M to $18.47M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about MBX Biosciences, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude